Document:

<PAGE>

                                                                   EXHIBIT 10.22

DATED                        19 MAY                             1998
--------------------------------------------------------------------------------

(1)                      BRITISH TECHNOLOGY GROUP LIMITED

                                     - and -

(2)                              LEUKOSITE, INC.

--------------------------------------------------------------------------------

                             SUPPLEMENTAL AGREEMENT
                        relating to the Licence Agreement
                          made between the same parties
                             dated 31(st) March 1997

--------------------------------------------------------------------------------
<PAGE>

THIS DEED made the 19(th) day of May 1998 between (1) BRITISH TECHNOLOGY GROUP
LIMITED whose company registration number is 2664412 and whose registered office
address is at 10 Fleet Place, Limeburner Lane, London, EC4M 7SB ("BTG") and (2)
LEUKOSITE INC of 215 First Street, Cambridge, MA 02142, USA ("the Licensee") is
SUPPLEMENTAL to the Licence Agreement made between the parties on 31st March
1997 ("the Licence Agreement")

WHEREAS:-

(A)  By a licence agreement effective 2(nd) May 1997 the Licensee granted a
     sub-licence to L&I Partners, L.P. a Delaware Limited Partnership having an
     address at 11550 1H 10 West Suite 300, San Antonio, Texas 78230, USA
     ("L&I")

(B)  The parties hereto have decided to enter into this Deed to clarify certain
     issues arising from the said sub-licence ("the Sub-Licence")

NOW IT IS AGREED THAT:-

1.   The words `or other legal entity' shall be deemed to be inserted after `and
     in the case of the Licensee any company' in the definition of "Group" in
     the License Agreement.

2.   The Licensee shall procure that if L&I contemplates legal proceedings
     against a third party under one or more of the Patents (as defined in the
     Licence Agreement) it shall first give notice to BTG.

3.   Clause 22 of the Licence Agreement also applies to this Agreement.

IN WINESS whereof this document has been executed as a Deed the day and year
first above written.

The COMMON SEAL of
BRITISH TECHNOLOGY GROUP
LIMITED was affixed to this Deed
in the presence of:-

                                   [Illegible]
                         Director / Authorised Signatory

                                   [Illegible]
                        Secretary / Authorised Signatory

The Common Seal of
LEUKOSITE INC. was affixed to
this Deed in the presence of

                      Director:         /s/ Christopher Mirabelli
                      Asst. Secretary:  /s/ Bob Gallahue<PAGE>

                                                                   EXHIBIT 10.23

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

DATED                        19(TH) MAY                             1998
--------------------------------------------------------------------------------

(1)                      BRITISH TECHNOLOGY GROUP LIMITED

                                     - and -

(2)                              LEUKOSITE, INC.

--------------------------------------------------------------------------------

                                DEED OF VARIATION

                          relating to Licence Agreement
                              dated 31st March 1997

--------------------------------------------------------------------------------
<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

THIS DEED made the 19(th) day of May 1998 BETWEEN (1) BRITISH TECHNOLOGY GROUP
LIMITED whose company registration number in England is 2664412 and whose
registered office is at 10 Fleet Place, London, EC4M 7SB ("BTG") and (2)
LEUKOSITE INC. of 215 First Street, Cambridge MA 02142, USA ("the Licensee") is
supplemental to the Licence Agreement made between the parties on the 31st March
1997 ("the Agreement").

NOW IT IS AGREED THAT:

1.   VARIATIONS TO THE AGREEMENT

     1.1  in clause 1.1.11 the wording after `Option 1' was replaced by `or
          Option 5 it shall be [**] Dollars ($[**])'.

     1.2  the words `any company' at the end of clause 1.1.15 were replaced by
          `any legal entity;'

     1.3  in clause 1.1.27 the existing definition of "Option 1" was replaced
          by:-

               The right to insert `or for any therapeutic indications in human
               transplantation (including bone marrow purging)' before `which is
               made or sold' in the definition of "the Product" (as varied from
               time to time)

     1.4  The existing definition of "the Options" was amended to include Option
          5.

     1.5  The following definition was inserted after existing clause 1.1.30:-

               "Option 5" the right to insert the following at the end of the
               definition of "the Product"

                    and any product containing or utilising Rat Campath
                    Antibodies for any therapeutic indication in human
                    transplantation (including bone marrow purging) which is
                    made or sold or otherwise disposed of, in any country, by or
                    on behalf of the Licensee or any sub-licensee

               and the right to insert the following at the end of clause 4.1:-

                    BTG also grants to the Licensee the right to make, have made
                    use and sell product containing or utilising Rat Campath
                    Antibodies for any therapeutic indication in human
                    transplantation (including bone marrow purging) but not for
                    any other purpose.

               and the right to insert `and the licences in respect of the Rat
               Campath Antibodies and Rat Cell Lines' before `shall be
               exclusive' in clause 4.3

<PAGE>

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

     1.6  The following definitions were inserted after the existing clause
          1.1.33:-

          "Rat Campath Antibodies"      [**] antibodies [**].

          "Rat Cell Lines"              [**] cell lines [**]

     1.7  the words `or for such other therapy for which Licensee has exercised
          its option under clause 4.2.1' were deleted from the definition of
          "Product"

     1.8  the following was added at the end of clause 4.2.2:-

     PROVIDED THAT:-

          (1)  The Licensee may exercise Option 5 without paying an Exercise Fee
               for it if at such time the Licensee has already exercised Option
               1; and

          (2)  In the case of Option 1 and Option 5 Leukosite shall use all
               reasonable endeavours to agree the development plan with both
               Professor Hermann Waldmann and Dr. Georffrey Hale prior to
               delivering the same to BTG (this being an additional requirement
               to those set out in clause 4.2.2.3)

          (3)  If the Licensee submits a development plan for Option 1 or Option
               5 and BTG is (at any time) notified by Professor Herman Waldman
               and Dr. Geoffrey Hale that they both consider such plan or plans
               unsatisfactory, then at the request of BTG the Licensee shall do
               one or other of the following (with the choice to be that of the
               Licensee):-

               (a)  procure supply free of charge to the University of Oxford
                    ("the University") Rat Campath Antibodies of sufficient
                    quality to enable the University to maintain its bone marrow
                    purging programme and in such quantity as the University
                    shall demand subject to the following maximum levels:-

                    [Campath - 1M - 100g per annum]
                    [Campath IG - 500g per annum]

               (b)  waive / surrender (as appropriate) the Licensee's rights to
                    exercise Option 5, or its rights deriving from exercise of
                    Option 5, such waiver / surrender to be in such form as BTG
                    shall reasonably request.

               Following the said request by BTG the Licensee shall promptly
               inform BTG of the licensee's decision on whether to opt for (a)
               or(b)
<PAGE>

     1.9  the following was added as a new clause 4.3.4:-

               the right of the inventors to supply (or sub-license the supply)
               of Rat Campath Antibodies for use as a therapeutic on a
               non-profit basis.

     1.10 the words `in relation to Products containing Campath 1H antibodies
          (on the one hand) and Products containing Rat Campath Antibodies (on
          the other) on a country by country basis' were substituted for `in
          each country' in clause 8.1.2;

     1.11 the following was added as a new clause 12.8:-

          The Licensee shall keep both Professor Hermann Waldman and Dr Geoffrey
          Hale informed, on a regular basis, as to the Licensee's plans to
          develop Campath 1H and/or the Rat Campath Antibodies for human
          transplantation, and on its progress with such development.

     1.12 the words `and the Rat Campath Antibodies and the Rat Cell-Lines' were
          inserted after `the know-how' in clause 17.4.1;

     1.13 the following was added as a new clause 23:-

          Rat Campath Antibodies
          ----------------------

          On the License exercising Option 5 BTG shall promptly arrange the
          supply of the Rat Cell-Lines to the Licensee or its nominee, whereupon
          the Licensee shall, (or if appropriate procure that the nominee
          shall):-

               23.1 maintain the Rat Cell-Lines in a viable state and use all
                    reasumable endeavours to minimise the risk of loss of or
                    damage to the same; and

               23.2 perform the obligations of clause 5.3 (mutatis mutandis) in
                    relation to the Rat Cell-Lines and the Rat Campath
                    Antibodies.

2.   Law and Jurisdiction

     2.1  This Agreement is to be read and construed in accordance with, and
          governed by, English law.

     2.2  The Licensee submits to the jurisdiction of the Commonwealth of
          Massachusetts. USA.

     IN WITNESS whereof this document has been executed as a Deed the day and
year first above written.
<PAGE>

THE COMMON SEAL of BRITISH
TECHNOLOGY GROUP LIMITED was
affixed to this Deed in the presence of:-

                                    [illegible]
                                    Director/Authorised Signatory

                                    [illegible]
                                    Secretary/Authorised Signatory

The COMMON SEAL of
LEUKOSITE INC was affixed to
this Deed in the presence of:-

                                    Director  [illegible]

                                    Asst. Secretary [illegible]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00021-of-00352.parquet"}]]